Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 1/20 | 0.43 |
| ▸ | TUBB known ✓ | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B known ✓ | P68363 | 1/20 | 0.43 |
| ▸ | TUBA4A known ✓ | P68366 | 1/20 | 0.43 |
| ▸ | TUBB4B known ✓ | P68371 | 1/20 | 0.43 |
| ▸ | TUBB3 known ✓ | Q13509 | 1/20 | 0.43 |
| ▸ | TUBB2A known ✓ | Q13885 | 1/20 | 0.43 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 1/20 | 0.43 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 1/20 | 0.43 |
| ▸ | TUBA1A known ✓ | Q71U36 | 1/20 | 0.43 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 1/20 | 0.43 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 1/20 | 0.43 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 1/20 | 0.43 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 1/20 | 0.43 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.33 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29441712 | 1.00 | POLB (0.48) | POLBMAPK1ATMTUBB4ATUBB | |
| SCHEMBL5393 | 0.98 | POLB (0.50) | POLBMAPK1ATMTUBB4ATUBB | |
| SCHEMBL1226224 | 0.98 | POLB (0.50) | POLBMAPK1ATMTUBB4ATUBB | |
| SCHEMBL29376241 | 0.98 | POLB (0.50) | POLBMAPK1ATMTUBB4ATUBB | |
| Phosphine SCHEMBL30259325 | 0.96 | POLB (0.48) | POLBMAPK1ATMTUBB4ATUBB | |
| Formic Acid SCHEMBL1091492 | 0.89 | POLB (0.43) | POLBMAPK1ATMTUBB4ATUBB | |
| SCHEMBL6639835 | 0.88 | POLB (0.70) | POLBMAPK1ATMFAAHMGLL | |
| SCHEMBL30273023 | 0.78 | POLB (0.38) | POLBMAPK1ATMDAOKDM4E | |
| Dicyclohexylcarbodiimide SCHEMBL14577062 | 0.77 | EPHX1 (0.39) | POLBMAPK1ATMTUBB4ATUBB | |
| SCHEMBL25400045 | 0.73 | FAAH (0.39) | POLBMAPK1ATMTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265878-B1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-13 | — | — | EP | claimed |
| EP-1882690-A2 | A process for the preparation of epothilone analogs and intermediates | Bristol-Myers Squibb Pharma Company (US) | 2008-01-30 | — | — | EP | claimed |
| US-RE39356-E1 | Process for the preparation of epothilone analogs | BRISTOL-MYERS SQUIBB CO. (US) | 2006-10-17 | — | — | US | claimed |
| US-6518421-B1 | Coupling agent for such reaction and palladium catalyst for lactonization | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-11 | — | — | US | claimed |
| US-20030004338-A1 | Process for the preparation of epothilone analogs | R-PHARM US OPERATING LLC | 2003-01-02 | — | — | US | claimed |
| EP-1265878-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILINE ANALOGS AND INTERMEDIATES | Bristol-Myers Squibb Company (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2002060904-A2 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2001070716-A1 | A PROCESS FOR THE PREPARATION OF EPOTHILONE ANALOGS AND INTERMEDIATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-27 | — | — | WO | claimed |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| CN-115068626-A | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-09-20 | — | — | CN | disclosed |
| US-11434278-B2 | Protein-polymer-drug conjugates | ASANA BIOSCIENCES, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| CN-105813655-B | Protein-polymer-drug conjugates | 阿萨纳生物科技有限责任公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| EP-0914321-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | Smithkline Beecham S.p.A. (IT) | 1999-05-12 | — | — | EP | disclosed |
| EP-0912511-A1 | 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | Smithkline Beecham S.p.A. (IT) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912539-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | Smithkline Beecham S.p.A. (IT) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001423-A1 | 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001436-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001443-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | TUBB4A 1223/4885TUBB 859/4885TUBA3C 1118/4885 |
| US-11434278-B2 | Protein-polymer-drug conjugates | PBRM1, STAMBP, TSPO | TUBB4A 1223/4885TUBB 859/4885TUBA3C 1118/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | TUBB4A 1574/4885TUBB 1164/4885TUBA3C 1966/4885 |
| US-20030004338-A1 | Process for the preparation of epothilone analogs | DHPS, SQLE, NOTUM | TUBB4A 853/4885TUBB 964/4885TUBA3C 1918/4885 |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | PBRM1, STAMBP, TSPO | TUBB4A 1193/4885TUBB 850/4885TUBA3C 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.